Biblio

Export 6 results:
Author Title Type [ Year(Asc)]
Filters: Author is Winblad, Bengt and First Letter Of Title is C  [Clear All Filters]
2025
A. Wimo, Handels, R., Blennow, K., K Kirsebom, B. - E., Selnes, P., Bon, J., Emersic, A., Gonzalez-Ortiz, F., Kramberger, M. Gregoric, Sköldunger, A., Speh, A., Timón-Reina, S., Vromen, E., Visser, P. Jelle, Winblad, B., and Fladby, T., “Cost-effectiveness of diagnosing and treating patients with early Alzheimer's disease with anti-amyloid treatment in a clinical setting.”, J Alzheimers Dis, p. 13872877251323231, 2025.
2021
J. Cummings, Schwartz, G. G., Nicholls, S. J., Khan, A., Halliday, C., Toth, P. P., Sweeney, M., Johansson, J. O., Wong, N. C. W., Kulikowski, E., Kalantar-Zadeh, K., Lebioda, K., Ginsberg, H. N., Winblad, B., Zetterberg, H., and Ray, K. K., “Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial.”, J Alzheimers Dis, vol. 83, no. 4, pp. 1703-1715, 2021.
A. Wimo, Belger, M., Bon, J., Jessen, F., Dumas, A., Kramberger, M. G., Jamilis, L., Johansson, G., Salas, A. Rodrigo, Gómez, O. Rodríguez, Sannemann, L., Stoekenbroek, M., Telleria, M. Gurruchaga, Valero, S., Vermunt, L., Waterink, L., Winblad, B., Visser, P. Jelle, Zwan, M., and Boada, M., “A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer's Disease: Results from the MOPEAD Project.”, J Alzheimers Dis, vol. 83, no. 3, pp. 1149-1159, 2021.
2017
R. L. H. Handels, Wimo, A., Dodel, R., Kramberger, M. G., Visser, P. Jelle, Molinuevo, J. Luis, Verhey, F. R. J., and Winblad, B., “Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia.”, J Alzheimers Dis, vol. 60, no. 4, pp. 1477-1487, 2017.
A. - M. Miller, Balasa, M., Blennow, K., Gardiner, M., Rutkowska, A., Scheltens, P., Teunissen, C. E., Visser, P. Jelle, Winblad, B., Waldemar, G., and Lawlor, B., “Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe.”, J Alzheimers Dis, vol. 60, no. 1, pp. 201-210, 2017.
2016
N. Lelental, Brandner, S., Kofanova, O., Blennow, K., Zetterberg, H., Andreasson, U., Engelborghs, S., Mroczko, B., Gabryelewicz, T., Teunissen, C., Mollenhauer, B., Parnetti, L., Chiasserini, D., Molinuevo, J. Luis, Perret-Liaudet, A., Verbeek, M. M., Andreasen, N., Brosseron, F., Bahl, J. M. C., Herukka, S. - K., Hausner, L., Frölich, L., Labonte, A., Poirier, J., Miller, A. - M., Zilka, N., Kovacech, B., Urbani, A., Suardi, S., Oliveira, C., Baldeiras, I., Dubois, B., Rot, U., Lehmann, S., Skinningsrud, A., Betsou, F., Wiltfang, J., Gkatzima, O., Winblad, B., Buchfelder, M., Kornhuber, J., and Lewczuk, P., “Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.”, J Alzheimers Dis, vol. 52, no. 1, pp. 51-64, 2016.